Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone

Sponsor
University of Campinas, Brazil (Other)
Overall Status
Completed
CT.gov ID
NCT01460355
Collaborator
(none)
23
1
2
21
1.1

Study Details

Study Description

Brief Summary

Two different treatments were given to large angle horizontal strabismus (eso and exotropia) adult patients who agree to participate of the study. Inform consents were required for participants. Group 1 (12 patients) received conventional recess-resect surgery plus intraoperative injection of botulinum toxin A (5U). Group 2 (11 patients) received only conventional recess-resect surgery. The patients were randomly located in one of the groups. The angles of horizontal deviation were compared between the groups before and six months after treatment.

Condition or Disease Intervention/Treatment Phase
  • Drug: Botulinum Toxin Type A
  • Drug: saline solution
Phase 4

Detailed Description

Patients underwent recess/resection surgery on the non-fixating eye using conventional technique under local anesthesia. The extent of surgery was determined based on our usual amounts. Before re-attaching the recessed muscle to the sclera, 5 units of botulinum toxin in 0.1 ml of hyaline solution were, or 0.1 ml of hyaline solution alone were was injected into the posterior muscle belly by the surgeon who was unaware of the contents of each syringe.

Study Design

Study Type:
Interventional
Actual Enrollment :
23 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Surgery Associated to Intraoperative Botulinum Toxin A for Large Angle Horizontal Strabismus: a Pilot Study
Study Start Date :
Sep 1, 2006
Actual Primary Completion Date :
Jun 1, 2007
Actual Study Completion Date :
Jun 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Botulinum toxin plus surgery

Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery

Drug: Botulinum Toxin Type A
injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
Other Names:
  • BTA
  • Placebo Comparator: Saline solution plus surgery

    Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure

    Drug: saline solution
    injection of 0,1ml of saline solution will be given to the recessed muscle
    Other Names:
  • saline
  • Outcome Measures

    Primary Outcome Measures

    1. percentage of decrease of the initial angle of strabismus [6 to 12 months]

      The percentages of decrease of the initial angle of strabismus were accessed by subtracting the final deviation of the initial deviation, dividing the result by the initial deviation and multiplying it by 100.

    Secondary Outcome Measures

    1. frequency of induced blepharoptosis [From the first to the last post operative day of follow up]

      The presence of induced blepharoptosis was detected by simple inspection and was reported as positive or negative.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • adults with large angle horizontal strabismus
    Exclusion Criteria:
    • oblique muscle disfunction

    • previous strabismus surgery

    • dissociated vertical deviation

    • paretic or restrictive deviation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 State University of Campinas Campinas São Paulo Brazil 13084-971

    Sponsors and Collaborators

    • University of Campinas, Brazil

    Investigators

    • Principal Investigator: Nilza Minguini, MD, PhD, University of Campinas, Brazil

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Nilza Minguini, MD, PhD, University of Campinas, Brazil
    ClinicalTrials.gov Identifier:
    NCT01460355
    Other Study ID Numbers:
    • Unicamp-CEP- 427/2006
    First Posted:
    Oct 26, 2011
    Last Update Posted:
    Oct 26, 2011
    Last Verified:
    Oct 1, 2011
    Keywords provided by Nilza Minguini, MD, PhD, University of Campinas, Brazil
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 26, 2011